This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally.View PLX key stats
Protalix BioTherapeutics Inc - PLX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Protalix BioTherapeutics Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate PROTALIX BIOTHERAPEUTICS INC (PLX) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and weak operating cash flow.